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Abstract Background: Nephropathic cystinosis is a rare
autosomal recessive disorder caused by mutations in the
CTNS gene, encoding for cystinosin, a carrier protein
transporting cystine out of lysosomes. Its deficiency leads
to cystine accumulation and cell damage in multiple organs,
especially in the kidney. In this study, we aimed to provide
the first report describing the mutational spectrum of
Egyptian patients with nephropathic cystinosis and their
genotype–phenotype correlation.
Methods: Fifteen Egyptian patients from 13 unrelated
families with infantile nephropathic cystinosis were eval-
uated clinically, biochemically, and genetically. Screening
for the common 57-kb deletion was performed by standard
multiplex PCR, followed by direct sequencing of the ten
coding exons, exon-intron interfaces, and promoter region.
Results: None of the 15 Egyptian patients had the 57-kb
deletion. Twenty-seven mutant alleles and 12 pathogenic
mutations were detected including six novel mutations: two
frameshift (c.260_261delTT; p.F87SfsX36, c.1032del-
CinsTG; p.F345CfsX19), one nonsense (c.734G>A; p.
W245fsX), two missense (c.1084G>A; pG362R,
c.560A>G; p.K187R), and one intronic splicing mutation
(IVS3+5g>t). A novel promoter region mutation (1-593-
41C>T) seemed to be detected but was excluded as a
pathogenic mutation by quantitative real-time PCR analy-
sis.
Conclusions: This study could be the basis for future
genetic counseling and prenatal diagnosis of patients with
nephropathic cystinosis in Egyptian and surrounding
populations. The screening for the 57-kb deletion is not
recommended anymore outside its geographical distribu-
tion, especially in the region of the Middle East. A common
Middle Eastern mutation (c.681G>A; E227E) was pointed
out and discussed.
Introduction
Nephropathic cystinosis is one of the leading hereditary
causes of renal Fanconi syndrome in children worldwide. It
is an autosomal recessive lysosomal storage disorder caused
by mutations of the CTNS gene located on chromosome
17p13 (Town et al. 1998). The CTNS gene is made up of 12
exons, the last ten encoding for cystinosin, a protein that
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facilitates cystine transport out of lysosomes. Defective
cystinosin-mediated cystine transport leads to the accumu-
lation and crystallization of cystine in cells of different
organs, particularly the kidney, cornea, and thyroid (Nester-
ova and Gahl 2013). Patients with infantile nephropathic
cystinosis (OMIM 219800), comprising about 95% of all
cases, usually develop renal Fanconi syndrome in the first
year of life and renal failure in the first decade if not
treated. Other less common types are the juvenile (OMIM
219900) and the non-nephropathic ocular cystinosis
(OMIM 219750) (Nesterova and Gahl 2013).
The aminothiol cysteamine is the only specific therapy
for cystinosis so far. It helps in the depletion of cystine
from lysosomes through different transporter mechanisms
(Butler and Zatz 1984); however, it does not completely
stop the progression of the disease and does not restore the
lost renal function. Early diagnosis and management of
nephropathic cystinosis is of utmost importance to delay
renal deterioration (Gahl et al. 1990) and other systems’
affection (Kimonis et al. 1995) and, hence, improves the
patient’s survival and quality of life.
The diagnosis of nephropathic cystinosis is confirmed by
elevated cystine concentration in white blood cells (WBC),
or even better in granulocytes (Levtchenko et al. 2004),
which is the diagnostic cornerstone. Molecular analysis of
the CTNS gene confirms the diagnosis and offers the
advantage of prenatal diagnosis (Nesterova and Gahl 2013).
Detection of corneal cystine crystals by a slit lamp
examination is another confirmatory sign, but a rather late
one as it is reasonably sensitive close to the second year of
life (Soliman et al. 2009).
Almost 100 CTNS mutations have been reported so far
in the literature (www.hgmd.cf.ac.uk). The most prevalent
is the 57-kb deletion removing the first ten exons of the
CTNS gene with its upstream sequence. It constitutes
approximately 75% of mutated alleles in cystinotic patients
from Northern European descent (Touchman et al. 2000).
However, CTNS gene mutations have been rarely reported
outside Europe and North America.
In this study, we evaluated CTNS mutations in 15
Egyptian pediatric patients with infantile nephropathic
cystinosis and commented on their genotype–phenotype
correlation. This would be the first report on the mutational
spectrum of nephropathic cystinosis in Egypt and in the
region of North Africa.
Patients and Methods
Patients
DNA samples of 15 Egyptian nephropathic cystinosis
patients (nine males/six females, 3–16 years) from 13
different families of pure Egyptian background were
obtained. Patients were recruited from the Center of
Pediatric Nephrology and Transplantation (CPNT), Cairo
University Children Hospitals, Cairo, Egypt, over the
period from November 2010 to June 2012; however, some
of them have been diagnosed and treated in the center for
several years. DNA was extracted from either EDTA blood
by the salting out technique or blood spots on filter paper
by QIAamp, DNA mini kit (Qiagen). The study was
approved by the institutional review board, and written
informed consents were obtained from subjects’ parents/
legal guardians.
Methods
Molecular analysis was performed at the laboratory of
pediatrics/pediatric nephrology at UZ Leuven, K.U.
Leuven. All patients were first screened for the 57-Kb
deletion by a standard multiplex PCR technique using
LDM1 and D17S829 primer sets as previously described
(Heil et al. 2001), and then direct sequencing of the ten
coding exons and exon–intron interfaces of the CTNS gene
(ENSG00000040531, ENST00000046640) (www.ensembl.
org) was performed (ABI 3100, Applied Biosystems). Data
were analyzed using SEQUENCE Pilot (JSI Medical
Systems). Promoter region sequencing was performed for
patients with unidentified mutant alleles (Phornphutkul
et al. 2001). Sequences of all used primers are available
upon request.
Mutation prediction analysis was performed for newly
detected variants using the following pathogenicity soft-
ware programs: PMut, Mutation Taster, PolyPhen2, Splice-
man, BDGP, and Automated Splice Site Analysis.
Total RNA was isolated from leukocytes of patient
2 (probable splicing mutation) and patient 12 (probable
promoter mutation) using RNeasy MiniKit (Qiagen).
Reverse transcription-PCR (RT-PCR) was performed using
Superscript III Reverse-Transcriptase (Life Technologies)
according to the manufacturer’s protocol. In patient 2,
cDNA amplification for the CTNS gene was performed
compared to a healthy control using the primers previously
described [forward: 50-CCTCTTCCAGTAACATTGAGG-
30 and reverse 50-CGCGTGCAGGCTGAAGAAGA-30]
(AlcÄntara-Ortigoza et al. 2008) crossing the exonic
boundaries and giving a product extending from exon 2 to
exon 9 (722 bp in normal individuals); the resulting
amplification product was directly sequenced.
In patient 12, cDNA was used for quantitative real-time
PCR (qPCR) (Rotor-Gene Q, Qiagen) together with
platinum Sybr Green PCR mix (Life Technologies), CTNS
cDNA primers mentioned above, and primers for GAPDH
as a reference gene. Three healthy control samples were
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assayed in the same run by qPCR. The patient and controls
were assayed each in triplicate. Cycling parameters were as
follows: 95C, 30 s; 60C, 60 s; 72C, 60 s for 40 cycles;
and then extension at 72C for 5 min. Resulting data were
expressed as percent of reduction in gene expression
compared to normal controls after normalization with GAPDH
using the 2-DDCT method (Livak and Schmittgen 2001).
Cystine assay in WBC was recently established and
performed at the Inherited Metabolic Disorder Laboratory
(IMDL), Center of Social and Preventive Medicine
(CSPM), Cairo University Children Hospitals. Cystine
assay was performed by LC-MS/MS (Micromass, Waters),
as previously described (Chabli et al. 2007), using the
internal standard d,l-cystine-2,20,3,3,30,30-d6 (C/D/N iso-
topes), L-cystine calibration curve, and a 3.0 x 50 mm,
3.5 m particle size Xterra C18 HPLC column.
Results
Fifteen Egyptian patients with infantile nephropathic
cystinosis were evaluated clinically, biochemically, and
genetically. Consanguinity was reported in ten out of 13
families, and corneal cystine crystals were detectable in all
patients. Age at presentation ranged from 4 to 12 months,
and age at diagnosis ranged from 5 months to 9 years.
Patients were already on cysteamine therapy at the time of
sampling for a period ranging from 2 to 84 months, on a
dosage ranging from 15 to 45 mg/kg/day. All patients were
below the 3rd percentiles for weight and height in their age
groups. One patient died (patient 8) at the age of 8 years
before completion of the study. One patient underwent renal
transplantation (patient 4) at the age of 14 years. Three
patients have ESRD, and four patients have hypothyroidism
and are on L-thyroxin replacement therapy. Cystine levels
in WBC ranged from 1.5 to 15.3 nmol ½ cystine/mg
proteins (Table 1).
None of the 15 Egyptian patients had the common
European 57-Kb deletion. Twelve pathogenic mutations
were identified representing 27 discovered mutant alleles
(Table 2). Ten out of 15 patients had homozygous
mutations. Six previously reported CTNS mutations were
detected in our study: c.829dup; p.T277NfsX19 (Besouw
et al. 2012), c.922G>A; G308R (Shotelersuk et al. 1998),
809_811delCCT; p.S270del (Attard et al. 1999), c.15G>A;
p.W5X (Kalatzis et al. 2002), c.681G>A; E227E
(Aldahmesh et al. 2009), and c.1015G>A; p.G339R
(Shotelersuk et al. 1998). All these mutations were previ-
ously associated with infantile nephropathic cystinosis in
various populations. Figure 1 presents the worldwide
geographical distribution of the previously reported CTNS
mutations detected in Egyptian patients.
Newly detected CTNS variants include two frameshift
mutations (c.260_261del; p.F87SfsX36 and c.1032del-
CinsTG; p.F345CfsX19), one nonsense mutation
(c.734G>A; p.W245fsX), two missense mutations
(c.1084G>A; pG362R and c.560A>G; p.K187R), and
one intronic splicing mutation (IVS3+5g>t) (Fig. 2). A
novel promoter region variant was also detected in a
homozygous state in patient 12 (1-593-41C>T)
corresponding to the important specificity protein-1 (Sp-1)
binding motif (GGCGGCG) that was reported to extend
from 1-593-46 to 1-593-40 in the CTNS promoter area
(Phornphutkul et al. 2001) (Fig. 2).
The newly detected variants were tested with different
predictive software programs. Table 3 provides a summary
for all prediction results. The frameshift and the nonsense
variants led to truncated proteins and were easily predicted
pathogenic. c.1084G>A in patient 10 replacing glycine
with arginine at position 362, which is a highly conserved
residue among different species, was also detected as being
pathogenic. The other missense variant (c.560A>G) in
patient 8 replacing lysine with arginine at position 187 was
expected to be neutral based on the amino acid change;
however, this mutation occurs at the second base before
exon–intron 8 interface (Fig. 2) and could be an exonic
splicing mutation as expected by three splicing evaluation
software programs. The intronic mutation (IVS35g>t) in
patient 2 was more strongly suspected to have a splicing
damaging effect during transcription (Table 3).
The splicing mutation (IVS3+5g>t) was confirmed by
demonstrating the skipping of exon 3 evidenced by
sequence analysis after RT-PCR (Fig. 3). On the other
hand, the promoter region mutation in patient 12 (1-593-
41C>T) led to a modest reduction (27  6.5%) in CTNS
RNA gene expression after normalization to GAPDH and
comparison with three healthy controls. To our regret, RNA
samples from patient 8 (c.560A>G) or his parents were
unobtainable.
Discussion
We here present the first report on the mutational spectrum
of Egyptian patients with nephropathic cystinosis. Thirteen
unrelated families and 15 patients representing a wide
geographical distribution within Egypt were screened for
the CTNS gene mutations.
Most of the Egyptian patients had a severe phenotype as
evident in Table 1, but this phenotypic severity could be
attributed to many factors. The CTNS genotype is definitely
an important one (Attard et al. 1999); however, delayed
diagnosis in many of our patients, underdosage due to
financial or logistical problems, and differences in response
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Table 2 Genotype of Egyptian patients with nephropathic cystinosis
Proband Mutant allele1 Mutant allele2 Location Protein effects Consequence of mutation Reference
1 c.829dup c.829dup Exon 10 p.T277NfsX19 Truncated protein at AA296 (Besouw et al
2012)
2 IVS3+5g>t IVS3+5g>t Intron 3 – Skipping of exon 3 This study
3 c.922G>A c.922G>A Exon 11 G308R AA change at TM6 (Shotelersuk
et al 1998)
4 809_811del 809_811del Exon 10 p.S270del AA deleted from TM5 (Attard et al
1999)
5a,5b c.829dup c.829dup Exon 10 p.T277NfsX19 Truncated protein at AA296 (Besouw et al
2012)
6 c.15G>A c.15G>A Exon 3 p.W5X Truncated protein at AA5 (Kalatzis et al
2002)
7 c.681G>A c.681G>A Exon 9 E227E Alternative splicing (Aldahmesh
et al 2009)
8 260_261delTT c.560A>G Exons 6
and 8
p.F87SfsX36, p.
K187R
Truncated protein at AA123,
Alternative splicing
This study
9 c.1015G>A c.1015G>A Exon 12 p.G339R AA change at TM7 (Shotelersuk
et al 1998)
10 c.1084G>A ND Exon 12 pG362R AA change at cytosolic LTM This study
11a,11b c.734G>A c.1032delCinsTG Exons 10
and 12
p.W245fsX, p.
F345CfsX19
Truncated protein at AA245,
Truncated protein at AA364
This study
12 ND ND – – – –
13 c.829dup c.829dup Exon 10 p.T277NfsX19 Truncated protein at AA296 (Besouw et al
2012)
AA, Amino acid; LTM, Lysosomal targeting motif; ND, Not detected; TM, Transmembrane domain; Families 5 and 11 have 2 siblings each (a)
and (b).
Egypt Saudi 
Arabia
Iran
Turkey
c.681G>A
c.829dup
c.922G>A
c.809_811del
c.15G>A
c.1015G>A
57-kb deletion
Fig. 1 Worldwide geographical distribution of 57-kb deletion and previously reported CTNS mutations detected in the Egyptian population. Oval:
geographical distribution of 57-kb deletion. Circle: geographical distribution of the Middle Eastern mutation c.681G>A
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to cysteamine therapy may all be implicated (Soliman et al.
2013).
In our series of patients, growth retardation was a
striking feature in almost all patients; however, more severe
cases were usually associated with truncating mutations
(Table 2). The recent introduction of growth hormone in the
therapeutic panel of Egyptian nephropathic cystinosis
patients hopefully will improve the overall growth pattern.
Although all therapeutic measures were taken to oppose the
effects of hypocalcemia and hypophosphatemia, still most
of our patients are complaining of rickets and some already
show skeletal deformities at relatively young ages. The only
patient who underwent renal transplantation (patient 4) is
doing well with normally functioning graft and is showing
increased annual height velocity post transplantation. Not
surprisingly though, she is still suffering remarkable growth
Proband 2: IVS3+5g>t (H)                                   Proband 8: c.260_261delTT; p.F87SfsX36 (h)
Proband 8: c.560A>G; p.K187R (h)       Proband 10: c.1084G>A; p.G362R (h)
Probands 11a, 11b: c.734G>A; p.W245fsX (h)        Probands 11a, 11b: c.1032delCinsTG; p.F345CfsX19 (h)
Proband 12: 1-593-41C>T (H)
61      +1     +2      +3     +4     +5     +6      +7      +8     +9    +10 258  259  260    261  262  263  264  265  266 267 268 
555   556   557    558   559   560     561    +1       +2     +3     +4 1079 1080 1081 1082 1083  1084  1085  1086  1087 1088 1089
729    730     731    732   733  734    735   736   737    738   739 1028   1029  1030 1031     1032  1033 1034   1035 1036  1037 
-46 -45 -44 -43 -42 -41 -40 -39 -38 -37 -36
Fig. 2 Newly discovered CTNS variants in Egyptian patients. H homozygous, h heterozygous
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retardation and residual genu valgum given the significantly
late diagnosis in this particular patient (at 9 years of age)
and the consequent therapeutic delay.
The detection of six novel mutations and six mutations
previously reported in 13 families denotes the marked
genetic heterogeneity of Egyptian patients with nephropathic
Table 3 Predicted effects of new CTNS variants
Variant Prediction
Deletions or insertions
c.260-261delTT; p.F87SfsX36 Frame shift
c.1032delCinsTG; p.F345CfsX19 Frame shift
Nonsense
c.734G>A; p.W245fsX Nonsense
Missense PMut (AA change) Mutation taster
(AA change/splice)
PolyPhen2 (AA change)
NN
output
Reliability Result Probability Result Score Result
c.1084G>A; p.G362R 0.8395 6 Pathogenic 0.999 Pathogenic 0.647 Possibly
damaging
c.560A>Ga; p.K187R 0.0145 9 Neutral 0.952 Pathogenic 0.002 Benign
Probable splicing variants Spliceman (splice) BDGP (splice) Automated splice site analysis
(splice)
Ranking Result Score Result Final/initial
binding
Result
IVS3+5g>t 0.85 Pathogenic 1.0>0.67 Pathogenic 6.6% Pathogenic
c.560A>Ga 0.55 Pathogenic 1.0>0.99 Neutral 20.4% Pathogenic
AA Amino acid
PMut: http://mmb2.pcb.ub.es:8080/PMut/; Mutation taster: www.mutationtaster.org/; PolyPhen2: genetics.bwh.harvard.edu/pph2/; Spliceman:
fairbrother.biomed.brown.edu/spliceman/; BDGP: www.fruitfly.org/seq_tools/splice.html; Automated splice site analysis: https://splice.uwo.ca/
a A missense mutation and a probable splicing mutation
Exon 2 Exon 4
Exon 2 Exon 3
Proband 2: IVS3+5g>t (RT-PCR)
Normal control (RT-PCR)
Fig. 3 RT-PCR/sequence analysis of the mutation (IVS3+5g>t) of patient 2 in which skipping of exon 3 of the CTNS gene is evident compared
to a healthy individual
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cystinosis, which is different from many populations in
which a single mutation may constitute over 50% of
causative mutations. Also the high rate of homozygous
mutations in our study (67%) sheds light on the gravity of
the role of consanguineous marriage in elevating the
incidence of nephropathic cystinosis and other autosomal
recessive disorders in Egypt and in other Arab countries with
similar and even higher rates of consanguineous marriages
(Tadmouri et al. 2009).
The novel mutations found in this study include the
frameshift mutation (c.260_261delTT; p.F87SfsX36)
detected in patient 8, converting phenylalanine at position
87 to serine and resulting in a truncated protein at AA 123,
completely abolishing the protein function. Likewise, the
other novel frameshift mutations detected in sisters 11a and
11b (c.1032delCinsTG; p.F345CfsX19) resulted in the
conversion of phenylalanine to cysteine at position 345
and a truncated protein at AA 364, disrupting the seventh
and final transmembrane domain of cystinosin (Attard et al.
1999). The nonsense mutation (c.734G>A; p.W245fsX)
also detected in patients 11a and 11b led to the conversion
of tryptophan at position 245 into a stop codon (TAG), thus
immediately stopping the protein translation.
The missense mutation (c.1084G>A; pG362R) detected
in patient 10 is the first reported mutation in the lysosomal
targeting motif of cystinosin (GYDQL) extending from AA
362 to 366. This mutation replaced the highly conserved
glycine at position 362 at the C-terminus of the protein with
the basic amino acid arginine. This charge alteration is
expected to disrupt the cytosolic lysosomal targeting motif
(Attard et al. 1999). Although previous intentional site-
directed mutagenesis of C-terminus lysosomal targeting
motif led to the redirection of most of cystinosin to the
plasma membrane, still partial localization to lysosomes
occurred, denoting the presence of a second lysosomal
targeting signal, which was identified in the third cytoplas-
mic loop (YFPQA) extending from AA 281 to 285
(Cherqui et al. 2001). This could be the reason of the
relatively milder phenotype of patient 10 (no metabolic
acidosis, rickets, limb deformity, or hypothyroidism)
(Table1).
The other missense mutation was detected in patient
8 (c.560A>G; p.K187R), and although exonic, it is highly
likely to cause alternative splicing, as it was detected as
being pathogenic by three different splicing software
programs: Mutation Taster, Spliceman, and Automated
Splice Site Analysis (Table 3). Unfortunately, the patient
with this mutation died recently at the age of 8 years from
intracranial hemorrhage complicating hemodialysis before
we could confirm the splicing nature of his mutation.
The intronic splice site mutation (IVS3+5g>t) detected
in patient 2 led to the skipping of exon 3 after RT-PCR/
sequencing analysis as the similar splicing mutation at the
same position (IVS3+5g>a), which was also demonstrated
to lead to exon 3 skipping in a Mexican patient with
nephropathic cystinosis (AlcÄntara-Ortigoza et al. 2008),
confirming the importance of the guanine base at the IVS+5
position for CTNS exon 3 transcription.
Promoter region mutations reported in the CTNS gene
are rare. Only three different mutations were reported in
eight patients (Phornphutkul et al. 2001, Mason et al.
2003). The most commonly reported is the mutation
causing infantile type (1-593-42G>C) which was discov-
ered in six patients, one from the USA and five from Italy.
The other two reported mutations (1-593-50G>T and
1-593-50insT) resulted in ocular cystinotic phenotypes.
All three mutations were located at or near a highly critical
region in the promoter area corresponding to the Sp-1
binding motif essential for gene transcription (Phornphutkul
et al. 2001). We here report the fourth promoter region
mutation at the Sp-1 binding motif in the CTNS gene
(1-593-41C>T) detected in patient 12 in our study in a
homozygous state. qPCR analysis of this patient’s RNA
sample showed only a modest reduction in CTNS gene
expression when compared to three control individuals
(27  6.5 %). This indicates that this variant is not the
mutation responsible for the patient phenotype (Table 1);
however, reducing CTNS gene expression in the first place
is also indicative of the importance of the Sp-1 binding
motif for CTNS gene transcription. Caution during the
interpretation of promoter region mutations is highly
recommended.
In addition to the 13 Egyptian cystinotic families, the
absence of the 57-kb deletion has been previously reported
in the region of the Middle East in 13 families from
Saudi Arabia (Aldahmesh et al. 2009), 10 from Turkey
(Topaloglu et al. 2012), and 24 from southwestern Iran
(Shahkarami et al. 2013). A single study in the Far East
(Thailand) also reported the absence of the 57-kb mutant
allele in six patients of Thai and Cambodian origins (Yeetong
et al. 2012). Apparently, this common mutation is restricted
to the Northern European/American populations and, to a
lesser extent, to countries of possible genetic contact as in
Italy (Mason et al. 2003) and Mexico (AlcÄntara-Ortigoza
et al. 2008). This supports the theory that this founder
mutation originated very recently during human evolution,
perhaps less than 2,000 years ago somewhere in Northern
Europe (Kalatzis and Antignac 2002); so it has not got the
chance to spread to remote ethnicities. Based on these
observations, we do not recommend anymore the routine
screening for the 57-kb deletion before CTNS sequencing in
populations outside its geographical distribution, at least in
the region of the Middle East.
The most common mutation detected in Egyptian
patients is c.829dup; p.T277NfsX19, discovered in a
homozygous state in four patients belonging to three
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unrelated families (6/26 or 23.1% of Egyptian familial
mutant alleles). This mutation is a frameshift mutation
starting at codon 277, leading eventually to a truncated
protein at amino acid 296. It was associated with increased
creatinine levels in two Egyptian unrelated patients (1 and
13) at the time of diagnosis (2 and 3 years, respectively),
and the latter patient is already complaining of hypothy-
roidism at 4 years (Table 1). This mutation has been
reported only once before in a heterozygous state in a
European patient (Besouw et al. 2012). It is apparently a
hot spot in Egypt and could be the focus for further
investigations. Apart from this mutation, all other detected
CTNS mutations in Egyptian patients were only present in a
single family.
In similar studies in the Middle East, only one mutation
was detected in all populations. This mutation was the
exonic splice site mutation c.681G>A; p.E227E,
completely abolishing the adjacent donor site at exon 9
and replacing it with a cryptic donor site (Aldahmesh et al.
2009). It comprises 39.5% of Iranian (Shahkarami et al.
2013), 20% of Turkish (Topaloglu et al. 2012), and 15.4%
of Saudi familial mutant alleles (Aldahmesh et al. 2009).
This mutation was not detected previously in European or
American populations (a pure Middle Eastern mutation),
and it was present in the Egyptian population in our study
in a homozygous state in a single patient (7.7% of familial
mutant alleles); so its prevalence decreases gradually upon
heading to the west (Fig. 1). This could suggest that the
origin of this founder mutation is Iran or perhaps a place
further to the east.
Other previously reported CTNS mutations detected in
our study include c.15G>A; p.W5X, which is a nonsense
mutation leading to truncated protein at AA 5 with
complete loss of function. c.922G>A; p.G308R and
c.1015G>A; p.G339R are two missense mutations that
were tested on the level of cystinosin protein carrier
function and led to absent carrier capability (Kalatzis
et al. 2004). Likewise, the small deletion c.809_811del; p.
S270del was tested functionally and resulted in almost
complete loss of function (Kalatzis et al. 2004). The most
widely distributed among the six previously reported
mutations in Egyptian patients was c.1015G>A; p.
G339R, as it was reported in Turkey (Topaloglu et al.
2012), Italy (Mason et al. 2003), Germany (Kiehntopf et al.
2002), France (Attard et al. 1999), Spain (Macías-Vidal
et al. 2009), the USA (Shotelersuk et al. 1998), and Canada
(Rupar et al. 2001), followed by c.922G>A; p.G308R
reported in Saudi Arabia (Aldahmesh et al. 2009), Italy
(Mason et al. 2003), France (Attard et al. 1999), Spain
(Macías-Vidal et al. 2009), and the USA (Shotelersuk et al.
1998). The mutation c.809_811del; p.S270del was also
relatively widespread, as it was reported in France (Attard
et al. 1999) and India (Tang et al. 2009) (Fig. 1).
The most common Egyptian mutation (c.829dup; p.
T277NfsX19) was completely absent in other studies from
the Middle East. Likewise, the most common mutation in the
Saudi population (1013 T>G; L338R), representing 34.6 %
of familial mutant alleles, was not detected in the three
surrounding populations, and apart from the founder mutation
(c.681G>A; E227E), there were no other mutations detected
in common among the Saudi, Turkish, and Iranian patients.
This is quite remarkable considering the long history of
commercial relations, invasions, and genetic contact between
these four close countries over the last few thousand years.
The newly detected mutations in our study may not be
restricted to the Egyptian population, as the cystinotic
genotypes of most Arab and all African populations are still
largely obscure. However, our study helps in the under-
standing of the genetic basis of this orphan disease and its
correlation with phenotypic features in this part of the
world where consanguinity is the rule, not the exception. It
also paves the way for future family counseling and
prenatal diagnosis in the region.
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